Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Market Closed - BME 11:35:21 2024-02-23 am EST 5-day change 1st Jan Change
11.5 EUR +4.31% Intraday chart for Grifols, S.A. +8.39% -25.62%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
European Equities Traded in the US as American Depositary Receipts Rise Friday, Set to End Week Up 1.5% MT
Global markets live: BAE Systems, HSBC, Nvidia, Tesla, Boeing... Our Logo
Grifols Rejects 'Misleading' Allegations in Gotham City Research's New Short-selling Report MT
Gotham City issues new report on Grifols, maintains questions over accounting practices RE
GRIFOLS SPOKESPERSON DID NOT IMMEDIATELY COMMENT ON NEW GOTHAM… RE
GOTHAM CITY RESEARCH ISSUES NEW REPORT ON GRIFOLS, MAINTAINS QU… RE
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading MT
Grifols Reports Positive Late-Stage Fibrinogen Trial Results MT
Grifols Unit's Acquired Fibrinogen Deficiency Treatment Meets Primary Endpoint in Phase 3 Trial MT
Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results CI
GRIFOLS : Grifols accelerates its governance improvements post the short-seller’s allegations Alphavalue
Grifols Announces Executive Changes CI
Grifols, S.A. Announces CEO Changes CI
Global markets live: BP, Palantir, Infineon, Toyota, UBS... Our Logo
European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading MT
Spain's Grifols Names New CEO MT
Grifols Appoints Nacho Abia as CEO MT
Spain's Grifols hires new CEO weeks after damaging short-seller report RE
Grifols hires new CEO, four weeks after short-seller Gotham City report RE
European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Move Lower in Tuesday Trading MT
Global markets live: United Airlines, Intel, Bayer, Spotify, Microsoft... Our Logo
Spain's Grifols Sues Gotham City Research in US Over Short-selling Report MT
Spain's Grifols sues Gotham City fund, JV over damaging report RE
SPAIN'S GRIFOLS SAYS IT FILED LAWSUIT IN NEW YORK AGAINST GOTHAM… RE
Chart Grifols, S.A.
More charts
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (77.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (14.9%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (5.4%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.3%), European Union (11.7%), the United States and Canada (63.6%) and other (19.4%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
11.5 EUR
Average target price
19.15 EUR
Spread / Average Target
+66.57%
Consensus
  1. Stock
  2. Equities
  3. Stock Grifols, S.A. - BME
  4. News Grifols, S.A.
  5. Grifols Unit Awarded Contract Expansion With US Defense Department to Develop Therapies for Botulinum Toxin
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer